U.S. markets open in 6 hours 32 minutes
  • S&P Futures

    4,348.00
    +22.50 (+0.52%)
     
  • Dow Futures

    33,884.00
    +159.00 (+0.47%)
     
  • Nasdaq Futures

    14,969.50
    +103.00 (+0.69%)
     
  • Russell 2000 Futures

    1,808.50
    +9.90 (+0.55%)
     
  • Crude Oil

    91.37
    +0.58 (+0.64%)
     
  • Gold

    1,860.90
    -5.20 (-0.28%)
     
  • Silver

    22.09
    -0.36 (-1.60%)
     
  • EUR/USD

    1.0585
    +0.0010 (+0.10%)
     
  • 10-Yr Bond

    4.5730
    0.0000 (0.00%)
     
  • Vix

    17.52
    +0.18 (+1.04%)
     
  • GBP/USD

    1.2212
    +0.0011 (+0.09%)
     
  • USD/JPY

    149.6310
    +0.3010 (+0.20%)
     
  • Bitcoin USD

    28,091.37
    +955.25 (+3.52%)
     
  • CMC Crypto 200

    603.01
    +24.25 (+4.19%)
     
  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     
  • Nikkei 225

    31,759.88
    -97.72 (-0.31%)
     

Avid Bioservices: Q3 Earnings Insights

Shares of Avid Bioservices (NASDAQ:CDMO) increased in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 116.67% over the past year to $0.01, which beat the estimate of ($0.03).

Revenue of $21,806,000 rose by 60.52% year over year, which beat the estimate of $19,070,000.

Looking Ahead

Avid Bioservices Raises Its FY21 Sales From $84M-$88M To $88M-$91m Vs $ 86.26M Estimates

How To Listen To The Conference Call

Date: Mar 08, 2021

Time: 04:30 PM

View more earnings on CDMO

ET Webcast URL: https://edge.media-server.com/mmc/p/i5yaj5yr

Price Action

Company's 52-week high was at $22.13

52-week low: $3.02

Price action over last quarter: Up 58.50%

Company Description

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.